Behavior of blood plasma glycan features in bladder cancer

Shadi Ferdosi, Thai H. Ho, Erik P. Castle, Melissa L. Stanton, Chad Borges

    Research output: Contribution to journalArticle

    1 Citation (Scopus)

    Abstract

    Despite systemic therapy and cystectomy, bladder cancer is characterized by a high recurrence rate. Serum glycomics represents a promising source of prognostic markers for monitoring patients. Our approach, which we refer to as “glycan node analysis”, constitutes the first example of molecularly “bottom-up” glycomics. It is based on a global glycan methylation analysis procedure that is applied to whole blood plasma/serum. The approach detects and quantifies partially methylated alditol acetates arising from unique glycan features such as α2–6 sialylation, β1–4 branching, and core fucosylation that have been pooled together from across all intact glycans within a sample into a single GC-MS chromatographic peak. We applied this method to 122 plasma samples from former and current bladder cancer patients (n = 72 former cancer patients with currently no evidence of disease (NED); n = 38 non-muscle invasive bladder cancer (NMIBC) patients; and n = 12 muscle invasive bladder cancer (MIBC) patients) along with plasma from 30 certifiably healthy living kidney donors. Markers for α2–6 sialylation, β1–4 branching, β1–6 branching, and outer-arm fucosylation were able to separate current and former (NED) cases from certifiably healthy controls (ROC curve c-statistics ~ 0.80); but NED, NMIBC, and MIBC were not distinguished from one another. Based on the unexpectedly high levels of these glycan nodes in the NED patients, we hypothesized that recurrence of this disease could be predicted by some of the elevated glycan features. Indeed, α2–6 sialylation and β1–6 branching were able to predict recurrence from the NED state using a Cox proportional hazards regression model adjusted for age, gender, and time from cancer. The levels of these two glycan features were correlated to C-reactive protein concentration, an inflammation marker and known prognostic indicator for bladder cancer, further strengthening the link between inflammation and abnormal plasma protein glycosylation.

    Original languageEnglish (US)
    Article numbere0201208
    JournalPLoS One
    Volume13
    Issue number7
    DOIs
    StatePublished - Jul 1 2018

    Fingerprint

    blood plasma
    Urinary Bladder Neoplasms
    Polysaccharides
    Blood
    polysaccharides
    Plasmas
    branching
    Glycomics
    blood serum
    Recurrence
    Muscle
    Muscle Neoplasms
    inflammation
    alditols
    Inflammation
    Sugar Alcohols
    Glycosylation
    Patient monitoring
    muscles
    neoplasms

    ASJC Scopus subject areas

    • Biochemistry, Genetics and Molecular Biology(all)
    • Agricultural and Biological Sciences(all)

    Cite this

    Ferdosi, S., Ho, T. H., Castle, E. P., Stanton, M. L., & Borges, C. (2018). Behavior of blood plasma glycan features in bladder cancer. PLoS One, 13(7), [e0201208]. https://doi.org/10.1371/journal.pone.0201208

    Behavior of blood plasma glycan features in bladder cancer. / Ferdosi, Shadi; Ho, Thai H.; Castle, Erik P.; Stanton, Melissa L.; Borges, Chad.

    In: PLoS One, Vol. 13, No. 7, e0201208, 01.07.2018.

    Research output: Contribution to journalArticle

    Ferdosi, Shadi ; Ho, Thai H. ; Castle, Erik P. ; Stanton, Melissa L. ; Borges, Chad. / Behavior of blood plasma glycan features in bladder cancer. In: PLoS One. 2018 ; Vol. 13, No. 7.
    @article{2ff8d5d8d0ae4bac9c531ce84fc6b705,
    title = "Behavior of blood plasma glycan features in bladder cancer",
    abstract = "Despite systemic therapy and cystectomy, bladder cancer is characterized by a high recurrence rate. Serum glycomics represents a promising source of prognostic markers for monitoring patients. Our approach, which we refer to as “glycan node analysis”, constitutes the first example of molecularly “bottom-up” glycomics. It is based on a global glycan methylation analysis procedure that is applied to whole blood plasma/serum. The approach detects and quantifies partially methylated alditol acetates arising from unique glycan features such as α2–6 sialylation, β1–4 branching, and core fucosylation that have been pooled together from across all intact glycans within a sample into a single GC-MS chromatographic peak. We applied this method to 122 plasma samples from former and current bladder cancer patients (n = 72 former cancer patients with currently no evidence of disease (NED); n = 38 non-muscle invasive bladder cancer (NMIBC) patients; and n = 12 muscle invasive bladder cancer (MIBC) patients) along with plasma from 30 certifiably healthy living kidney donors. Markers for α2–6 sialylation, β1–4 branching, β1–6 branching, and outer-arm fucosylation were able to separate current and former (NED) cases from certifiably healthy controls (ROC curve c-statistics ~ 0.80); but NED, NMIBC, and MIBC were not distinguished from one another. Based on the unexpectedly high levels of these glycan nodes in the NED patients, we hypothesized that recurrence of this disease could be predicted by some of the elevated glycan features. Indeed, α2–6 sialylation and β1–6 branching were able to predict recurrence from the NED state using a Cox proportional hazards regression model adjusted for age, gender, and time from cancer. The levels of these two glycan features were correlated to C-reactive protein concentration, an inflammation marker and known prognostic indicator for bladder cancer, further strengthening the link between inflammation and abnormal plasma protein glycosylation.",
    author = "Shadi Ferdosi and Ho, {Thai H.} and Castle, {Erik P.} and Stanton, {Melissa L.} and Chad Borges",
    year = "2018",
    month = "7",
    day = "1",
    doi = "10.1371/journal.pone.0201208",
    language = "English (US)",
    volume = "13",
    journal = "PLoS One",
    issn = "1932-6203",
    publisher = "Public Library of Science",
    number = "7",

    }

    TY - JOUR

    T1 - Behavior of blood plasma glycan features in bladder cancer

    AU - Ferdosi, Shadi

    AU - Ho, Thai H.

    AU - Castle, Erik P.

    AU - Stanton, Melissa L.

    AU - Borges, Chad

    PY - 2018/7/1

    Y1 - 2018/7/1

    N2 - Despite systemic therapy and cystectomy, bladder cancer is characterized by a high recurrence rate. Serum glycomics represents a promising source of prognostic markers for monitoring patients. Our approach, which we refer to as “glycan node analysis”, constitutes the first example of molecularly “bottom-up” glycomics. It is based on a global glycan methylation analysis procedure that is applied to whole blood plasma/serum. The approach detects and quantifies partially methylated alditol acetates arising from unique glycan features such as α2–6 sialylation, β1–4 branching, and core fucosylation that have been pooled together from across all intact glycans within a sample into a single GC-MS chromatographic peak. We applied this method to 122 plasma samples from former and current bladder cancer patients (n = 72 former cancer patients with currently no evidence of disease (NED); n = 38 non-muscle invasive bladder cancer (NMIBC) patients; and n = 12 muscle invasive bladder cancer (MIBC) patients) along with plasma from 30 certifiably healthy living kidney donors. Markers for α2–6 sialylation, β1–4 branching, β1–6 branching, and outer-arm fucosylation were able to separate current and former (NED) cases from certifiably healthy controls (ROC curve c-statistics ~ 0.80); but NED, NMIBC, and MIBC were not distinguished from one another. Based on the unexpectedly high levels of these glycan nodes in the NED patients, we hypothesized that recurrence of this disease could be predicted by some of the elevated glycan features. Indeed, α2–6 sialylation and β1–6 branching were able to predict recurrence from the NED state using a Cox proportional hazards regression model adjusted for age, gender, and time from cancer. The levels of these two glycan features were correlated to C-reactive protein concentration, an inflammation marker and known prognostic indicator for bladder cancer, further strengthening the link between inflammation and abnormal plasma protein glycosylation.

    AB - Despite systemic therapy and cystectomy, bladder cancer is characterized by a high recurrence rate. Serum glycomics represents a promising source of prognostic markers for monitoring patients. Our approach, which we refer to as “glycan node analysis”, constitutes the first example of molecularly “bottom-up” glycomics. It is based on a global glycan methylation analysis procedure that is applied to whole blood plasma/serum. The approach detects and quantifies partially methylated alditol acetates arising from unique glycan features such as α2–6 sialylation, β1–4 branching, and core fucosylation that have been pooled together from across all intact glycans within a sample into a single GC-MS chromatographic peak. We applied this method to 122 plasma samples from former and current bladder cancer patients (n = 72 former cancer patients with currently no evidence of disease (NED); n = 38 non-muscle invasive bladder cancer (NMIBC) patients; and n = 12 muscle invasive bladder cancer (MIBC) patients) along with plasma from 30 certifiably healthy living kidney donors. Markers for α2–6 sialylation, β1–4 branching, β1–6 branching, and outer-arm fucosylation were able to separate current and former (NED) cases from certifiably healthy controls (ROC curve c-statistics ~ 0.80); but NED, NMIBC, and MIBC were not distinguished from one another. Based on the unexpectedly high levels of these glycan nodes in the NED patients, we hypothesized that recurrence of this disease could be predicted by some of the elevated glycan features. Indeed, α2–6 sialylation and β1–6 branching were able to predict recurrence from the NED state using a Cox proportional hazards regression model adjusted for age, gender, and time from cancer. The levels of these two glycan features were correlated to C-reactive protein concentration, an inflammation marker and known prognostic indicator for bladder cancer, further strengthening the link between inflammation and abnormal plasma protein glycosylation.

    UR - http://www.scopus.com/inward/record.url?scp=85050377835&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85050377835&partnerID=8YFLogxK

    U2 - 10.1371/journal.pone.0201208

    DO - 10.1371/journal.pone.0201208

    M3 - Article

    VL - 13

    JO - PLoS One

    JF - PLoS One

    SN - 1932-6203

    IS - 7

    M1 - e0201208

    ER -